Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis

Zheng-Rong Li,Zhao Wang,Bao-He Zhu,Yu-Long He,Jun-Sheng Peng,Shi-Rong Cai,Jin-Ping Ma,Wen-Hua Zhan
DOI: https://doi.org/10.1007/s00595-006-3437-9
2007-01-01
Surgery Today
Abstract:Purpose In gastric carcinoma, high expression of PRL-3 , a protein tyrosine phosphatase, is associated with lymph node metastasis. We studied the relationship between PRL-3 expression and peritoneal metastasis in gastric carcinoma. Methods Immunohistochemical analysis using the anti- PRL-3 antibody was done in 639 patients with gastric carcinoma including 89 with peritoneal metastases. We then compared the clinicopathologic characteristics of the PRL-3 -positive and PRL-3 -negative carcinomas. Results PRL-3 was expressed in 70.4% of the primary gastric carcinomas overall; in 80.9% of the cancers with peritoneal metastasis and in 68.7% of those without peritoneal metastasis ( P = 0.020). PRL-3 expression was higher in peritoneal metastasis than in the corresponding primary gastric cancers ( P = 0.028). PRL-3 expression was correlated with tumor stage (coefficient = 0.343, P = 0.01) and cancer progression, including lymphatic invasion (coefficient = 0.325, P = 0.02), extent of lymph node metastasis (coefficient = 0.322, P = 0.01), and peritoneal metastasis (coefficient = 0.316, P = 0.03). Patients who were PRL-3 -negative had a better survival rate than those who were PRL-3 -positive at all stages (stage I: log-rank P = 0.046, Wilcoxon P = 0.048; stage II: log-rank P = 0.035, Wilcoxon P = 0.041; stage III: log-rank P = 0.027, Wilcoxon P = 0.033; stage IV: log-rank P = 0.032, Wilcoxon P = 0.030). Conclusions Peritoneal metastasis appears to be correlated with PRL-3 expression, tumor stage, lymphatic invasion, and extent of lymph node metastasis. PRL-3 expression was negatively correlated with prognosis in patients with gastric cancer.
What problem does this paper attempt to address?